Last reviewed · How we verify
APC8015F
APC8015F is a therapeutic cancer vaccine designed to stimulate an immune response against prostate cancer cells.
APC8015F is a therapeutic cancer vaccine designed to stimulate an immune response against prostate cancer cells. Used for Prostate cancer.
At a glance
| Generic name | APC8015F |
|---|---|
| Sponsor | Dendreon |
| Drug class | cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
APC8015F is a type of active immunotherapy that uses a patient's own immune cells to recognize and attack cancer cells. The vaccine is designed to stimulate the immune system to produce a specific type of immune cell called a T-cell, which can recognize and kill prostate cancer cells.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Pain
- Infection
- Fever
- Nausea
Key clinical trials
- Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |